Blog

Dosimetry tells you the dose. It doesn’t tell you the decision.

Learn why absorbed dose data alone isn't enough for radiopharmaceutical dose optimization, and how BED,…

CertaraJuly 7, 2026

Guide

5 Key Principles of Modern PK/PD in 2026

Explore other Phoenix solutions to enhance your PK/PD workflow and discover how Phoenix helps you…

CertaraJune 30, 2026

Blog Case Study

63 Runs and No Convergence: When RsNLME Succeeded Where Other PK/PD Solutions Couldn’t

After 63 failed runs on a 16-ODE neutropenia model, RsNLME achieved PK/PD convergence on the…

Stephen DuffullJune 23, 2026

Poster

Machine Learning-Based Covariate Selection for Population Pharmacokinetic Modeling

Authors: Ibtissem Rebai (Certara), Stephen Duffull (Certara), Ayman Akil (Certara), Anna Largajolli (Certara), Floris Fauchet…

CertaraJune 22, 2026

Poster

Shaping the future of AI/ML in pharmacometrics through collaboration, education and best practices

Discover how the AI/ML Special Interest Group is advancing responsible artificial intelligence in pharmacometrics through…

CertaraJune 22, 2026

On-Demand Webinar

Model Smarter, Not Harder: Introducing Model Designer

Watch Model Designer on demand: Certara's browser based tool for faster NLME model discovery, configuration,…

CertaraJune 10, 2026

Poster

Translating Targeted Radiotherapies from Mouse to Human Using QSP: A Pluvicto Case Study

Download this poster to see how Certara used quantitative systems pharmacology (QSP) to translate ¹⁷⁷Lu-PSMA-617…

CertaraJune 9, 2026

Poster

Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies

Explore how population PK modeling predicts absorbed dose and biologically effective dose for radioligand therapies.

CertaraJune 9, 2026

Blog

Beyond Compliance: What ICH M15 Means for the Future of Drug Development

Explore how ICH M15 is shaping regulatory expectations for Model-Informed Drug Development (MIDD), including model…

CertaraJune 9, 2026

Video

Applying AI-Driven Biosimulation to Drug Discovery

Certara President Leif Pedersen explains how PBPK and QSP modeling, proven across 125+ FDA-approved drugs,…

CertaraJune 2, 2026

Modeling and Simulation – PK/PD

Dosimetry tells you the dose. It doesn’t tell you the decision.

5 Key Principles of Modern PK/PD in 2026

63 Runs and No Convergence: When RsNLME Succeeded Where Other PK/PD Solutions Couldn’t

Machine Learning-Based Covariate Selection for Population Pharmacokinetic Modeling

Shaping the future of AI/ML in pharmacometrics through collaboration, education and best practices

Model Smarter, Not Harder: Introducing Model Designer

Translating Targeted Radiotherapies from Mouse to Human Using QSP: A Pluvicto Case Study

Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies

Beyond Compliance: What ICH M15 Means for the Future of Drug Development

Applying AI-Driven Biosimulation to Drug Discovery

Newsletter sign up

Quick links

Solutions

Contact